Selenium is a
trace element that exerts certain
insulin-like actions in vitro. In this study, we evaluated its in vivo effects on the
glucose homeostasis of rats made diabetic and
insulin-deficient by
streptozotocin. Na2SeO4 was administered ad libitum in
drinking water and/or food for 10 weeks. The elevated plasma
glucose levels (approximately 25 mmol/l) and glucosuria (approximately 85 mmol/day) of untreated rats were decreased by 50 and 80%, respectively, by
selenate treatment. The beneficial effect of
selenate was also evident during oral and intravenous
glucose tolerance tests: the integrated
glucose responses were decreased by 40-50% as compared to those in untreated rats. These effects were not due to an increase in plasma
insulin levels. Compared to non-diabetic rats, pancreatic
insulin reserves were reduced by more than 90% in treated and untreated diabetic rats. The hepatic activities and
mRNA levels of two key glycolytic
enzymes,
glucokinase and
L-type pyruvate kinase were blunted in diabetic rats. They increased approximately two- to threefold after
selenate treatment, to reach 40-75% of the values in non-diabetic rats. In contrast, elevated activity and
mRNA levels of the gluconeogenic
enzyme,
phosphoenolpyruvate carboxykinase, were reduced by 40-65% after
selenate administration. Since
selenate induced a moderate decrease in
body weight due to an anorexigenic effect, we checked that there was no improvement of
glucose homeostasis or hepatic
glucose metabolism in an additional group of calorie-restricted diabetic rats, which was weight-matched with the
selenate group. In addition, no obvious toxic side-effects on the kidney or liver were observed in the rats receiving
selenate. In conclusion,
selenate induces a sustained improvement of
glucose homeostasis in
streptozotocin-diabetic rats by an
insulin-like action, which involves partial correction of altered pretranslational regulatory mechanisms in liver metabolism.